Melinta Therapeutics, Inc. (MLNT)


Melinta Therapeutics, Inc. (MLNT)

$1.69 USD

0.17 (-9.14%)

Updated Jun 14 6:55pm

Add MLNT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 322 in Biotech

See all “A” rated Strong Buy stocks

MLNT Daily Price Range
MLNT 52-Week Price Range

MLNT News Stream

Event/Time News Detail Start End Change
Loading, please wait...
View All MLNT News

Melinta Therapeutics, Inc. (MLNT) Company Bio


Melinta Therapeutics, Inc., formerly Cempra, Inc., is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP). Solithromycin has therapeutic potential and activity to target pathogenic bacteria. It has completed two pivotal Phase III trials for solithromycin to treat CABP, as of December 31, 2016. Its Fusidic acid is an antibiotic and the Company is exploring its use for the long-term oral treatment for refractory bone and joint infections (BJI), including prosthetic joint infections, which are caused by staphylococci, including S. aureus, methicillin-resistant S. aureus and other gram-positive bacteria.

MLNT Stock Chart More Charts


MLNT Price/Volume Stats

Current price $1.69
Prev. close $1.86
Day low $1.62
Day high $1.83
50-day MA $3.54
200-day MA $9.15
52-week high $46.00
52-week low $1.62
Volume 349,700
Avg. volume 416,807
Dividend yield N/A
Market Cap 19.91M

MLNT Social Stream


Loading social stream, please wait...

View Full MLNT Social Stream

MLNT Returns

1-mo -44.95%
3-mo -63.97%
6-mo -68.70%
1-year -96.27%
3-year -99.63%
5-year -99.36%
YTD -57.22%
2018 -95.00%
2017 12.86%
2016 -91.01%
2015 32.41%
2014 89.75%
Page generated in 0.4286 seconds.